The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...
The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders ...
Though the S&P 500 dipped earlier this month, it's important to keep in mind that we're still in a very positive market ...
The novel drugs work by mimicking the gut hormone GLP-1, which lowers blood sugar and limits the appetite. Treatments such as ...
As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...
Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive ...
The company said that, based on a pharmacokinetic study, it has plumped for a once-daily, modified-release formulation of GLP-1 agonist danuglipron that will start dose optimisation studies later ...
Pfizer recently selected a once-daily formulation of danuglipron as its candidate for phase 3 testing, while Roche recently reported phase 1 results with its candidate CT-966 - a candidate ...
In the same month, Pfizer announced plans to advance its once-a-day weight-loss pill, danuglipron, into clinical trials during the second half of this year, with results expected in the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback